---
schema_version: "secwatch.filing_event.v1"
accession: "0001326732-23-000028"
form_type: "8-K"
ticker: "XNCR"
cik: "0001326732"
company_name: "Xencor Inc"
filed_at: "2023-09-19T23:59:59+00:00"
generated_at: "2026-06-10T13:09:18.003275+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Xencor adds Barbara Klencke, M.D., to board; board expands to eight members

## Summary
- Board increased from 7 to 8 members; Dr. Klencke appointed effective Sept 15, 2023.
- Dr. Klencke receives initial stock option with Black-Scholes value of $550,000, vesting over 3 years.
- Annual cash retainer of $50,000 for board service; standard indemnification agreement.
- Dr. Klencke previously CMO and CDO at Sierra Oncology; led Ojjaara approval for myelofibrosis.
- Also serves on boards of eFFECTOR Therapeutics, Immune-Onc Therapeutics, and TScan Therapeutics.

## SEC filing metadata
- accession: 0001326732-23-000028
- form_type: 8-K
- ticker: XNCR
- cik: 0001326732
- company_name: Xencor Inc
- filed_at: 2023-09-19T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326732/000132673223000028/0001326732-23-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326732/000132673223000028/xncr-20230915.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326732-23-000028
- JSON: https://secwatch.observer/filing/0001326732-23-000028.json
- Plain text: https://secwatch.observer/filing/0001326732-23-000028.txt

## Key facts
- Executive change
  Barbara Klencke was appointed as Director at Xencor Inc.
  - Action: appointed
  - Role: Director
  source text: On September 15, 2023, the Board of Directors of the Company (the “Board”) was increased from seven to eight board members and Barbara Klencke, M.D., was appointed to serve as a new member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326732/000132673223000028/0001326732-23-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.